HBM Holdings (SEHK:2142) Valuation Check After Positive LET003 Obesity Antibody Preclinical Data

Simply Wall St.05-26

HBM Holdings (SEHK:2142) is in focus after Harbour BioMed reported preclinical data for LET003, an ACVR2A/2B-targeting antibody developed using its AI-based Hu-mAtrIx platform, showing superior ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638685035?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-26 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638685035","market":"sg","top_or_hot":-1,"title":"HBM Holdings (SEHK:2142) Valuation Check After Positive LET003 Obesity Antibody Preclinical Data","media":"Simply Wall St.","content":"<div>\n<p>HBM Holdings (SEHK:2142) is in focus after Harbour BioMed reported preclinical data for LET003, an ACVR2A/2B-targeting antibody developed using its AI-based Hu-mAtrIx platform, showing superior ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-positive-let003\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings (SEHK:2142) Valuation Check After Positive LET003 Obesity Antibody Preclinical Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings (SEHK:2142) Valuation Check After Positive LET003 Obesity Antibody Preclinical Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-26 05:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-positive-let003><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HBM Holdings (SEHK:2142) is in focus after Harbour BioMed reported preclinical data for LET003, an ACVR2A/2B-targeting antibody developed using its AI-based Hu-mAtrIx platform, showing superior ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-positive-let003\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4168","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-positive-let003","article_id":"2638685035","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-check-after-positive-let003","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638685035","pubTimestamp":1779744032,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"HBM Holdings (SEHK:2142) is in focus after Harbour BioMed reported preclinical data for LET003, an ACVR2A/2B-targeting antibody developed using its AI-based Hu-mAtrIx platform, showing superior pharmacokinetics compared with several competitors.\nSee our latest analysis for HBM Holdings.\nAt a share price of HK$12.15, HBM Holdings has seen the 30 day share price return fall 13.21%, even as the 1 year total shareholder return is 37.91% and the 3 year total shareholder return is very large. This...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4168":"多种金属与采矿","BK1161":"生物科技","DRAM":"Roundhill Memory ETF","BK1574":"生物医药B类股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","02142":"和铂医药-B","BK1583":"高瓴概念","HBM":"HudBay Minerals Inc"},"translate_title":"HBM Holdings(SEHK：2142)LET003肥胖抗体临床前数据阳性后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02142":0.9,"DRAM":1.5,"HBM":0.9},"content_text":"HBM Holdings (SEHK:2142) is in focus after Harbour BioMed reported preclinical data for LET003, an ACVR2A/2B-targeting antibody developed using its AI-based Hu-mAtrIx platform, showing superior pharmacokinetics compared with several competitors. See our latest analysis for HBM Holdings. At a share price of HK$12.15, HBM Holdings has seen the 30 day share price return fall 13.21%, even as the 1 year total shareholder return is 37.91% and the 3 year total shareholder return is very large. This suggests that momentum has softened recently compared with its longer track record. If this kind of AI driven drug development interests you, it can be worth widening your search with a screener focused on 128 healthcare AI stocks With HBM Holdings trading at HK$12.15 and a large 3 year total return already on the scoreboard, investors now have to ask: is the stock still undervalued, or is the market already pricing in future growth? AdvertisementPrice-to-Earnings of 14.7x: Is it justified? Based on the preferred metric, HBM Holdings trades on a P/E of 14.7x, which sits below several benchmarks and suggests the market is applying a relatively modest earnings multiple at the current HK$12.15 share price. The P/E ratio compares what investors are currently paying for each dollar of earnings and is often used for profitable biopharmaceutical companies because earnings can capture the effect of recently commercialised products and licensing income. For HBM Holdings, the picture is mixed. On one hand, earnings have grown very quickly over the past five years, and return on equity is high at 25.1%. On the other hand, there is a high level of non cash earnings, earnings are forecast to decline by an average of 4.9% per year over the next three years, and the stock is trading above the HK$9 estimate from the SWS DCF model for future cash flows. Against this backdrop, the current 14.7x multiple sits above the estimated fair P/E of 14.1x. The fair ratio model suggests the market could move toward this level. Compared with peers, HBM Holdings looks inexpensive on this same metric. Its 14.7x P/E is below the Hong Kong Biotechs industry average of 20.5x and well below the wider Asian Biotechs peer average of 35.1x. This indicates the stock is pricing in lower earnings expectations than many sector peers despite its recent earnings growth profile. Explore the SWS fair ratio for HBM Holdings Result: Price-to-Earnings of 14.7x (ABOUT RIGHT) However, investors still face risks, including forecast earnings declines of 4.9% a year, and a share price above the HK$9 SWS DCF estimate. Find out about the key risks to this HBM Holdings narrative. Another View: DCF Says The Stock Looks Expensive While the 14.7x P/E looks reasonable against peers, the SWS DCF model tells a different story. With HBM Holdings at HK$12.15 versus an estimated HK$9 future cash flow value, the stock screens as overvalued on this method. Which signal do you put more weight on? Look into how the SWS DCF model arrives at its fair value. 2142 Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out HBM Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 212 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With mixed signals on valuation and sentiment, it helps to look at the data yourself and act while the information is fresh in mind. To weigh the upside against the downside in detail, take a closer look at the 2 key rewards and 2 important warning signs. Looking for more investment ideas? If you are weighing your next move, now is the time to expand your watchlist and compare HBM Holdings with other stocks that fit clear, data driven criteria.  Spot potential mispricings early and review screener containing 530 high quality undiscovered gems that combine strong fundamentals with lower market attention. Prioritise resilience first and check 309 resilient stocks with low risk scores to focus on companies with more measured risk profiles. Strengthen your core holdings and use the solid balance sheet and fundamentals stocks screener (391 results) to find stocks backed by more robust financial positions.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HBM Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638685035","isCrawlerRequest":true}